- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04293484
Cortico-Spinal tDCS as Rehabilitative Intervention in Amyotrophic Lateral Sclerosis (tDCS_MND_2)
Cortico-Spinal tDCS as Rehabilitative Intervention in Amyotrophic Lateral: a Randomized, Double-blind, Sham-controlled Trial Followed by an Open-label Phase
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease, which is a group of neurological disorders that selectively affect motor neurons, the cells that control voluntary muscles of the body. The disorder causes muscle weakness and atrophy throughout the body due to the degeneration of the upper and lower motor neurons. Current drugs approved for ALS treatment only modestly slow disease progression.
Transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been demonstrated to modulate cerebral excitability in several neurodegenerative disorders and modulate intracortical connectivity measures.
In this randomized, double-blind, sham-controlled study followed by an open-label phase, the investigators will evaluate whether a repetition of two-weeks' treatment with bilateral motor cortex anodal tDCS and spinal cathodal tDCS, after a six months interval, may further outlast clinical improvement in patients with amyotrophic lateral sclerosis and can modulate intracortical connectivity, at short and long term.
Study Overview
Status
Detailed Description
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease, which is a group of neurological disorders that selectively affect motor neurons, the cells that control voluntary muscles of the body. The disorder causes muscle weakness and atrophy throughout the body due to the degeneration of the upper and lower motor neurons. Current drugs approved for ALS treatment only modestly slow disease progression.
Transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been demonstrated to modulate cerebral excitability in several neurodegenerative disorders and modulate intracortical connectivity measures.
The present randomized, double-blind, sham-controlled study followed by an open-label phase will investigate a repetition of two-weeks' treatment with bilateral motor cortex anodal tDCS and spinal cathodal tDCS, after a six months interval, may further outlast clinical improvement in patients with amyotrophic lateral sclerosis and modulate intracortical connectivity, at short and long term.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
BS
-
Brescia, BS, Italy, 25100
- AO Spedali Civili
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a diagnosis of probable, laboratory-supported probable, or definite amyotrophic lateral sclerosis according to the El Escorial revised criteria
- Disease duration ≤ 24 months
- Disease progression in the past 3 months
- Score ≥ 2 at the item "swallowing" of the ALS Functional Rating Scale Revised
- Score ≥ 2 at the item "walking" of the ALS Functional Rating Scale Revised
- Treatment with steady regimen of riluzole for a minimum of 1 month before study entry, and desiring its continuation
- Able to give informed consent
- Written informed consent
Exclusion Criteria:
- Motor neuron diseases other than ALS
- Severe head trauma in the past
- History of seizures
- History of ischemic stroke or hemorrhage
- Pacemaker
- Metal implants in the head/neck region
- Severe comorbidity
- Intake of illegal drugs
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Real tDCS - Real tDCS
10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
|
10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
|
Sham Comparator: Sham tDCS - Real tDCS
10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
|
10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Muscle Strength From Baseline
Time Frame: Baseline - 2 weeks - 2 month - 6 months - 6 months and 2 weeks - 8 months - 12 months
|
A megascore is obtained by summing scores of single muscles (shoulder abductors, elbow flexors and extensors, wrist flexors, thumb opponent, hip flexors, knee flexors and extensors, and ankle dorsiflexors and extensors on both sides) manually evaluated according to the Medical Research Council (MRC) scale, which ranges from 0 (no movement) to 5 (normal contraction). The score for each muscle is summed, with scores ranging from 100 (no impairment) to 0 (most severe impairment). |
Baseline - 2 weeks - 2 month - 6 months - 6 months and 2 weeks - 8 months - 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Short-interval Intracortical Inhibition (SICI) From Baseline
Time Frame: Baseline - 2 weeks - 2 month - 6 months - 6 months and 2 weeks - 8 months - 12 months
|
By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of tDCS on short-interval intracortical inhibition (SICI) from baseline
|
Baseline - 2 weeks - 2 month - 6 months - 6 months and 2 weeks - 8 months - 12 months
|
Change in the ALSFRS-R Score From Baseline
Time Frame: Baseline - 2 weeks - 2 month - 6 months - 6 months and 2 weeks - 8 months - 12 months
|
Change in the ALS Functional Rating Scale (ALSFRS-R) score from baseline.
The ALSFRS provides a physician-generated estimate of the patient's degree of functional impairment, which can be evaluated serially to objectively assess any response to treatment or progression of disease.
The ALSFRS includes ten questions that rate the patients level of functional impairment in performing one of ten common tasks.
Each task is rated on a five-point scale from 0 (can't do) to 4 (normal ability).
Individual item scores are summed to produce a reported score of between 40 (no impairment) and 0 (severe impairment).
|
Baseline - 2 weeks - 2 month - 6 months - 6 months and 2 weeks - 8 months - 12 months
|
Change of Quality of Life From Baseline: ALSAQ-40 Scale
Time Frame: Baseline - 2 weeks - 2 month - 6 months - 6 months and 2 weeks - 8 months - 12 months
|
Change of quality of life from baseline evaluated with the ALSAQ-40 scale. The Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ) is a patient self-report health status scale. The ALSAQ is specifically used to measure the subjective well-being of patients with amyotrophic lateral sclerosis. There are 40 items/questions with 5 discrete scales: physical mobility (10 items), activities of daily living and independence (10 items), eating and drinking (3 items), communication (7 items), emotional reactions (10 items). Patients are asked to think about the difficulties they may have experienced during the last two weeks (e.g. I have found it difficult to feed myself). Patients are asked to indicate the frequency of each event by selecting one of 5 options (Likert scale): never/rarely/sometimes/often/always or cannot do at all. The total ranges from 0 (no impairment) to 160 (severe impairment). |
Baseline - 2 weeks - 2 month - 6 months - 6 months and 2 weeks - 8 months - 12 months
|
Change of Quality of Life From Baseline: EQ-5D-5L Scale
Time Frame: Baseline - 2 weeks - 2 month - 6 months - 6 months and 2 weeks - 8 months - 12 months
|
Change of quality of life from baseline evaluated with the EQ-5D-5L scale.
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.
The scale ranges from 5 (no impairment) to 25 (severe impairment).
|
Baseline - 2 weeks - 2 month - 6 months - 6 months and 2 weeks - 8 months - 12 months
|
Change of Quality of Life From Baseline: EQ-VAS Scale
Time Frame: Baseline - 2 weeks - 2 month - 6 months - 6 months and 2 weeks - 8 months - 12 months
|
Change of quality of life from baseline evaluated with the EQ-VAS scale.
The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'.
The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.
The scale ranges from 0 (severe impairment) to 100 (no impairment).
|
Baseline - 2 weeks - 2 month - 6 months - 6 months and 2 weeks - 8 months - 12 months
|
Change in Caregiver Burden (CBI)
Time Frame: Baseline - 2 weeks - 2 month - 6 months - 6 months and 2 weeks - 8 months - 12 months
|
Change of quality of life from baseline evaluated with the CBI scale.
The CBI scale is 24- item scale designed to assess the experience of caregivers of older people.
The multidimensional instrument assesses five domains of burden (time-dependence, developmental, physical, social, and emotional).
Items are scored on a 4-point scale, ranging from "not at all descriptive" to "very descriptive".
The scale ranges from 0 (no impairment) to 96 (severe impairment).
|
Baseline - 2 weeks - 2 month - 6 months - 6 months and 2 weeks - 8 months - 12 months
|
Change Intracortical Facilitation (ICF) From Baseline
Time Frame: Baseline - 2 weeks - 2 month - 6 months - 6 months and 2 weeks - 8 months - 12 months
|
By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of tDCS on intracortical facilitation (ICF) from baseline.
|
Baseline - 2 weeks - 2 month - 6 months - 6 months and 2 weeks - 8 months - 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Barbara Borroni, MD, Università degli Studi di Brescia
Publications and helpful links
General Publications
- Lefaucheur JP, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, Cotelli M, De Ridder D, Ferrucci R, Langguth B, Marangolo P, Mylius V, Nitsche MA, Padberg F, Palm U, Poulet E, Priori A, Rossi S, Schecklmann M, Vanneste S, Ziemann U, Garcia-Larrea L, Paulus W. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol. 2017 Jan;128(1):56-92. doi: 10.1016/j.clinph.2016.10.087. Epub 2016 Oct 29.
- Benussi A, Alberici A, Cotelli MS, Dell'Era V, Cantoni V, Bonetta E, Manenti R, Filosto M, Morini R, Datta A, Thomas C, Padovani A, Borroni B. Cortico-spinal tDCS in ALS: A randomized, double-blind, sham-controlled trial. Brain Stimul. 2019 Sep-Oct;12(5):1332-1334. doi: 10.1016/j.brs.2019.06.011. Epub 2019 Jun 8. No abstract available.
- Menon P, Geevasinga N, Yiannikas C, Howells J, Kiernan MC, Vucic S. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol. 2015 May;14(5):478-84. doi: 10.1016/S1474-4422(15)00014-9. Epub 2015 Apr 3. Erratum In: Lancet Neurol. 2015 Jun;14(6):566.
- Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in frontotemporal dementia. Brain. 2011 Sep;134(Pt 9):2582-94. doi: 10.1093/brain/awr195. Epub 2011 Aug 11.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NP2743 v2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis With Dementia
-
University Hospital, ToulouseRecruitingAmyotrophic Lateral Sclerosis With DementiaFrance
-
Northwestern UniversityCompletedAmyotrophic Lateral Sclerosis (ALS) | Lou Gehrig's Disease | Primary Lateral Sclerosis (PLS) | Familial Amyotrophic Lateral Sclerosis | ALS With Frontotemporal Dementia (ALS/FTD) | Motor Neuron Disease (MND) | Sporadic ALS (SALS)United States
-
Assistance Publique - Hôpitaux de ParisUnknownHealthy Subjects, Patients With Amyotrophic Lateral Sclerosis, Patients With Shoulder SurgeryFrance
-
BiogenRecruitingAmyotrophic Lateral Sclerosis Associated With a SOD1 Gene MutationUnited States, Canada, Spain, Australia, Germany, Italy, Japan, Korea, Republic of, United Kingdom, Belgium, Brazil, France, Poland, Sweden
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Massachusetts, WorcesterEnrolling by invitationMotor Neuron Disease | Amyotrophic Lateral Sclerosis | Muscular Dystrophy | Frontotemporal Dementia | Miyoshi Myopathy | Amyotrophic Lateral Sclerosis, Sporadic | PLS | Lou Gehrigs Disease | Familial Disease | Amyotrophic Lateral Sclerosis With DementiaUnited States
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingEvaluation of the Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in Patients With Amyotrophic Lateral Sclerosis
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
Clinical Trials on Anodal bilateral motor cortex and cathodal spinal tDCS
-
Azienda Socio Sanitaria Territoriale degli Spedali...CompletedAmyotrophic Lateral SclerosisItaly
-
New York UniversityRecruiting
-
Azienda Socio Sanitaria Territoriale degli Spedali...CompletedAtaxia | Multiple System Atrophy | Spinocerebellar Ataxias | Spinocerebellar Ataxia 3 | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Ataxia With Oculomotor Apraxia | CANVASItaly
-
Azienda Socio Sanitaria Territoriale degli Spedali...CompletedCerebellar Ataxia | Multiple System Atrophy | Spinocerebellar Ataxias | Spinocerebellar Degenerations | Spinocerebellar Ataxia 3 | Friedreich Ataxia | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Ataxia, Spinocerebellar | Ataxia, Cerebellar | Ataxia With Oculomotor ApraxiaItaly
-
Seoul National University HospitalRusk Rehabilitation HospitalRecruitingStroke | Rehabilitation | Transcranial Direct Current Stimulation | Motor RecoveryKorea, Republic of
-
Universidade Federal de PernambucoUnknown
-
University Hospital TuebingenGerman Center for Diabetes ResearchUnknownInsulin Resistance | Transcranial Direct Current StimulationGermany
-
Assiut UniversityCompletedPain, PostoperativeEgypt, United Kingdom
-
Assiut UniversityUniversity College London Hospitals; Swansea UniversityCompleted
-
The University of Texas Health Science Center,...TerminatedAcquired Brain InjuryUnited States